Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor beta chain repertoire and reduces the level of T-cell oligoclonality.
Major T-cell receptor beta chain variable region (TCRBV) repertoire perturbations are temporally associated with the down-regulation of viremia during primary human immunodeficiency virus (HIV) infection and with oligoclonal expansion and clonal exhaustion of HIV-specific cytotoxic T lymphocytes (CTLs). To determine whether initiation of antiretroviral therapy (ART) or highly active antiretroviral therapy (HAART) during primary infection influences the dynamics of T-cell-mediated immune responses, the TCRBV repertoire was analyzed by semiquantitative polymerase chain reaction in serial blood samples obtained from 11 untreated and 11 ART-treated patients. Repertoire variations were evaluated longitudinally. Stabilization of the TCRBV repertoire was more consistently observed in treated as compared with untreated patients. Furthermore, the extent and the rapidity of stabilization were significantly different in treated versus untreated patients. TCRBV repertoire stabilization was positively correlated with the slope of HIV viremia in the treated group, suggesting an association between repertoire stabilization and virologic response to treatment. To test whether stabilization was associated with variations in the clonal complexity of T-cell populations, T-cell receptor (TCR) heteroduplex mobility shift assays (HMAs) were performed on sequential samples from 4 HAART-treated subjects. Densitometric analysis of HMA profiles showed a reduction in the number of TCR clonotypes in most TCRBV families and a significant decrease in the total number of clonotypes following 7 months of HAART. Furthermore, a biphasic decline in HIV-specific but not heterologous CTL clones was observed. This indicates that ART leads to a global reduction of CD8(+) T-cell oligoclonality and significantly modulates the mobilization of HIV-specific CTL during primary infection. (Blood. 2000;95:1743-1751)
Soudeyns
H
H
Laboratory of AIDS Immunopathogenesis, Division of Infectious Diseases, Department of Internal Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Campi
G
G
Rizzardi
G P
GP
Lenge
C
C
Demarest
J F
JF
Tambussi
G
G
Lazzarin
A
A
Kaufmann
D
D
Casorati
G
G
Corey
L
L
Pantaleo
G
G
D000208:Acute Disease; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000494:pharmacology; D002999:Clone Cells / Q000276:immunology; D016049:Didanosine / Q000008:administration & dosage / Q000494:pharmacology; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D015333:Gene Rearrangement, beta-Chain T-Cell Antigen Receptor; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors; D015497:HIV-1; D006801:Humans; D019469:Indinavir / Q000008:administration & dosage / Q000494:pharmacology; D019259:Lamivudine / Q000008:administration & dosage / Q000494:pharmacology; D008213:Lymphocyte Activation; D016133:Polymerase Chain Reaction; D012194:RNA-Directed DNA Polymerase / Q000008:administration & dosage / Q000494:pharmacology; D019258:Saquinavir / Q000008:administration & dosage / Q000494:pharmacology; D013602:T-Lymphocytes, Cytotoxic / Q000187:drug effects* / Q000276:immunology; D014766:Viremia / Q000188:drug therapy* / Q000276:immunology; D015215:Zidovudine / Q000008:administration & dosage / Q000494:pharmacology
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D019259:Lamivudine; D015215:Zidovudine; D019469:Indinavir; D054303:HIV Reverse Transcriptase; D012194:RNA-Directed DNA Polymerase; D016049:Didanosine; D019258:Saquinavir